Ucb S.A. (OP: UCBJF )

73.54 UNCHANGED

Streaming Delayed Price Updated: 12:45 PM EST, Nov 29, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	73.54
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	73.54
Today's Range	73.54 - 73.54
52wk Range	76.83 - 98.29
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts

August 31, 2023

Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and

Via Benzinga

Performance

YTD	-11.61%	-11.61%
1 Month	-0.62%	-0.62%
3 Month	-14.77%	-14.77%
6 Month	-20.88%	-20.88%
1 Year	-0.62%	-0.62%

More News

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults

June 27, 2023

Via Benzinga

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path

February 14, 2023

Via Benzinga

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval

March 28, 2022

Via Benzinga

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

February 08, 2022

Via Benzinga

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study

January 21, 2022

Via Benzinga

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

January 19, 2022

Via Benzinga

UCB Gets EU Approval For Bimekizumab In Psoriasis

August 25, 2021

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.